AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Louis Brenner, MD, Senior Vice President, will present an overview of the Company at the 2008 Citi Global Healthcare Conference on Thursday, May 22 at 11:30 a.m. ET. The conference is being held May 21-22, 2008 in New York City.
A live audio webcast of the presentation will be accessible through the Investors section of the Company’s website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until June 4, 2008.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.
Ferumoxytol, the Company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in chronic kidney disease patients. The Company has released data on all four planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic agent in chronic kidney disease patients. The Company submitted a New Drug Application for marketing approval of ferumoxytol with the U.S. Food and Drug Administration (FDA) in December 2007, which was accepted for filing by the FDA in February 2008.
Contacts:
Carol Miceli, 617-498-3361
cmiceli@amagpharma.com
